title: Pathogenesis of thrombocytopenia in cyanotic congenital heart disease.
abstract: Although a significant minority of patients with cyanotic congenital heart disease (CCHD) are thrombocytopenic, the pathogenesis and prevalence have not been established. This study was designed to address these 2 issues. We included 105 patients with CCHD (60 men and 45 women; aged 21 to 54 years). Systemic arterial oxygen saturations were 69% to 78%. Hematocrits were 62% to 74% with normal iron indexes. In 26 of 105 patients (25%), platelet counts were <100x10(9)/L. The diagnosis was Eisenmenger syndrome in all 26 patients with thrombocytopenia. Platelet production was determined by flow cytometric reticulated platelet counts. Megakaryocyte mass was determined indirectly by thrombopoietin levels. Disseminated intravascular coagulation was based on prothrombin time, activated partial thromboplastin time, and D-dimers. Platelet activation was determined by levels of platelet factor 4 and beta thromboglobulin. Reference ranges were derived from 20 normal acyanotic controls. A reduction in absolute reticulated platelet counts implied decreased platelet production (p<0.001). Normal thrombopoietin levels implied normal megakaryocyte mass. Normal prothrombin time, activated partial thromboplastin time, and D-dimers excluded disseminated intravascular coagulation. Normal platelet factor 4 and beta thromboglobulin indicated absent or minimal platelet activation. Twenty-five percent of the patients with CCHD were thrombocytopenic because platelet production was decreased despite normal megakaryocyte mass. We hypothesized that right-to-left shunts deliver whole megakaryocytes into the system arterial circulation, bypassing the lungs where megakaryocytic cytoplasm is fragmented into platelets, thus reducing platelet production. In conclusion, platelet counts in CCHD appear to represent a continuum beginning with low normal counts and ending with thrombocytopenia.
authors.affiliation: The Ahmanson/UCLA Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Lill
authors.forename: Joseph K
authors.initials: JK
authors.lastname: Perloff
authors.forename: John S
authors.initials: JS
authors.lastname: Child
mesh_terms: D000328:Adult; D015150:Echocardiography, Doppler; D004541:Eisenmenger Complex / Q000150:complications* / Q000175:diagnosis; D005260:Female; D005434:Flow Cytometry; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000378:metabolism; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors; D013921:Thrombocytopenia / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D001620:beta-Thromboglobulin / Q000378:metabolism
chemical_list: D001620:beta-Thromboglobulin; D010978:Platelet Factor 4